# SF1126 for Patients With Relapsed or Refractory Neuroblastoma

> **NCT02337309** · PHASE1 · TERMINATED · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 4 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** SF1126

## Key facts

- **NCT ID:** NCT02337309
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-09
- **Primary completion:** 2018-05-22
- **Final completion:** 2018-05-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Low patient accrual
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337309, "SF1126 for Patients With Relapsed or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT02337309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*